Navigation Links
Regado Biosciences, Inc. Introduces REG3, a Novel Aptamer-Based Inhibitor of Glycoprotein VI and its Matched Active Control Agent, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
Date:11/17/2010

BASKING RIDGE, N.J., Nov. 17, 2010 /PRNewswire/ -- Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced that Steven L. Zelenkofske, D.O., F.A.C.C., Senior Vice President and Chief Medical Officer, and Chris Rusconi, Ph.D., Senior Vice President and Chief Scientific Officer, presented a poster about REG3 at the AHA Scientific Sessions meeting on November 17, 2010 at 9:30 a.m. CST in Chicago, IL.  

The poster, entitled "Discovery of a Novel Aptamer-Based Inhibitor of GPVI and its Matched Active Control Agent," illustrates the use of Regado's proprietary technology platform to identify a novel aptamer-control agent pair targeting GPVI. GPVI, which mediates collagen-induced platelet activation, is a novel target for a new antiplatelet agent.  High levels of GPVI are associated with the onset of multiple diseases, including diabetes, ACS, peripheral vascular disease and stroke.  

REG3, Regado's third development program, represents the first identification of an actively controllable GPVI antagonist and the first anti-platelet agent capable of providing active control of the duration and intensity of anti-platelet therapy.  IND-enabling studies are ongoing and first-in-human clinical studies are anticipated to begin in 2011.

The poster is coauthored by Christopher P. Rusconi, Ph.D., Juliana M. Layzer, Brian G. Stell, Sanjoy K. Mahanty, Ryan J. Quick, Tadeusz K. Wyrzykiewicz, Ph.D., Douglas G. Brooks, Ph.D. and Steven L. Zelenkofske, D.O., F.A.C.C., all from Regado Biosciences.

ABOUT REGADO BIOSCIENCESRegado Biosciences, Inc. is a private biopharmaceutical company pioneering a new therapeutic technology with the creation and development of proprietary controllable aptamer drug systems.  Each system comprises a nuclease-stabilized RNA aptamer, the therapeutic effect of which can be reversed partially or completely in real time
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
2. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
3. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
4. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
5. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
6. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
7. Regado Biosciences Releases Positive Phase 2a Data for the Reversible Anticoagulant System REG1 at the European Society of Cardiology Congress In Barcelona, Spain
8. Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 17, 2009
9. Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009
10. Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010
11. Regado Biosciences to Present at the 2010 Wells Fargo Healthcare Conference on June 24, 2010 in Boston, Massachusetts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Mass. , May 23, 2013  Haemonetics Corporation (NYSE: ... Lindop , CFO & EVP-Business Development, will present at ... Conference in Boston, MA on May ... http://photos.prnewswire.com/prnh/20120206/NE47232LOGO ) The public may access ... About Haemonetics Haemonetics (NYSE: ...
(Date:5/23/2013)...  MGC Diagnostics Corporation (NASDAQ: MGCD ) ... scheduled a conference call to discuss its financial results ... April 30, 2013. The call will be at 4:30 ... will report financial results for the second quarter of ... May 30, 2013. (Logo: http://photos.prnewswire.com/prnh/20120821/LA60189LOGO ...
(Date:5/23/2013)... Bio-Holdings Ltd. (TASE: HDST, OTC: HADSY), a publicly ... property developed and owned by Hadassah University Hospital, ... center, today announced that its portfolio company, Cell ... Israeli Ministry of Industry and Commerce, Office of ... and advance clinical trials. Cell Cure,s development budget ...
Breaking Medicine Technology:MGC Diagnostics Corporation to Report Second Quarter Fiscal 2013 Financial Results on Thursday, May 30, 2013 2Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support 2
... Oct. 28 Octapharma Group and Fresenius Kabi ... regarding the use of Fresenius Kabi,s HESylation® Technology ... the agreement, Fresenius Kabi will license its proprietary ... based on hydroxyethyl starch ("HES") which will be ...
... , MALVERN, Pa., Oct. 28 Featuring the lowest ... Siemens Healthcare,s SOMATOM® Definition Flash dual-source computed tomography (CT) ... for Children, Orlando, Fla., to better serve its pediatric ... of the radiation dose that systems previously required to ...
Cached Medicine Technology:Octapharma Group and Fresenius Kabi Enter Into an Exclusive License, Development and Supply Agreement for a HESylated Recombinant Protein 2Octapharma Group and Fresenius Kabi Enter Into an Exclusive License, Development and Supply Agreement for a HESylated Recombinant Protein 3Siemens Delivers Flash Speed, Lowest Dose to Arnold Palmer Hospital for Children 2Siemens Delivers Flash Speed, Lowest Dose to Arnold Palmer Hospital for Children 3
(Date:5/24/2013)... (PRWEB) May 24, 2013 ResortQuest Real ... joined the Dayna Feher team at the firm’s Bethany ... the Delaware resorts her home in 1975. Her real ... worked in all aspects of the real estate business ... the past 12 years, a licensed sales associate. ...
(Date:5/24/2013)... Mirena IUD lawyers at the Rottenstein Law Group are ... than 59,229 complaints since 2004 from women claiming they suffered ... as the Mirena IUD.* , Among the most common of ... where the IUD came out on its own. There are ... article. “Abdominal pain is also common, with 3,774 complaints. And ...
(Date:5/24/2013)... (LA JOLLA, Calif.) (PRWEB) May 24, 2013 ... letter to House Appropriators and the California congressional ... them to restore sequestered industry user fees paid ... 2013, and to ensure that future across-the-board cuts ... as part of the FY14 Agriculture, Rural Development ...
(Date:5/24/2013)... GA (PRWEB) May 24, 2013 Started in ... held in Orlando. 2013 marks AMTC’s 31st anniversary. SHINE ... family, starting with supermodel Millie Lewis and her daughter, Carey ... top agents, managers, casting directors, and music professionals including the ... Arts and XP Media. They are kings of Hollywood and ...
(Date:5/24/2013)... 2013 Area homeowners dreaming about owning a ... tubs to choose from at factory-direct pricing during the ... event takes place at Emerald Pool and Patio ... Jacuzzi, the industry's leading hot tub brand, scheduled the event ... The event will feature popular hot tub models at up ...
Breaking Medicine News(10 mins):Health News:Tammy Mushrush Joins ResortQuest Real Estate® and the Dayna Feher Team 2Health News:Sufferers of Alleged Mirena IUD Side Effects Lodge More Than 59,000 Complaints With FDA, Rottenstein Law Group LLP Notes 2Health News:California Biomedical Industry Leaders Urge Congress to Take Action on FDA User Fees for FY2014 2Health News:California Biomedical Industry Leaders Urge Congress to Take Action on FDA User Fees for FY2014 3Health News:AMTC’s Summer SHINE Event Coming to Orlando’s Luxurious Gaylord Palms July 2-7, 2013 2Health News:Truckload of Jacuzzi® Hot Tubs Rolls into Bend, Oregon on May 24, 2013 for Sales Event 2
... 30 Military Officers Association of America ... (Ret), pulled no punches in expressing MOAA,s objection to ... inpatient copays by $110 per day for retired servicemembers, family ... and extremely disappointed that there would be any copay increase ...
... at UCSF Medical Center have begun enrollment for an early-stage ... adult stem cell therapy for patients who have just experienced ... is part of a multi-center national study. The cells ... bone marrow of healthy adult donors. Depending on their location ...
... it lowered risk of neurological problems later , WEDNESDAY, Sept. ... body temperature of oxygen-deprived newborns reduces the risk for neurological ... risk of death or severe disability. , Still, the findings, ... England Journal of Medicine , help fill a crucial gap ...
... ... Jonathan Kraft , ... (Vocus) September 30, 2009 -- The Boston biotechnology industry will get an early look at ... October 27, 2009 at Harvard Medical School. , , ,At the one-day event, recently funded ...
... Simmons firm, a leading national law firm in the fight ... Miles for Meso 5K run/walk on Sunday, October 11, in ... www.milesformeso.org . , The Simmons firm ... in Alton, Ill. Nearly 500 runners and walkers registered, and ...
... DALLAS, Sept. 30 The Sleep Center at Baylor University ... American Academy of Sleep Medicine. The center at Baylor ... in North Texas. , "Accreditation provides formal recognition ... for patients suffering from sleep disorders," said David L. ...
Cached Medicine News:Health News:MOAA Decries 21% TRICARE Inpatient Copay Hike 2Health News:Cardiac stem cell trial seeks to treat some heart attack patients 2Health News:Cardiac stem cell trial seeks to treat some heart attack patients 3Health News:Cooling Helps Oxygen-Deprived Newborns 2Health News:Cooling Helps Oxygen-Deprived Newborns 3Health News:Boston Biotech R&D Conference to Showcase Next-Generation Newsmakers and Massachusetts as Leader in Biotech Discovery 2Health News:Boston Biotech R&D Conference to Showcase Next-Generation Newsmakers and Massachusetts as Leader in Biotech Discovery 3Health News:Simmons Law Firm Presents Second 'Miles for Meso' Walk/Run Fundraiser 2Health News:Sleep Center at Baylor Dallas One of Select Centers in North Texas to Receive Accreditation 2
... panel is designed for medical imaging. The 18 inch ... and ultrasound. It can be mounted on a wall ... It allows for RGB, s-video and composite inputs with ... in VGA input. In VGA mode, its resolution is ...
... fixation. Completely resorbable, it presented surgeons with ... the most thoroughly proven product of its ... with system enhancements that make it even ... system means that application of this proven ...
... The intra-operative MR system ... intra-operative tool for radiologists ... goal of the system ... valuable adjunct to standard ...
... ultrasound A-scan Sonomed-315 is intended for visualization ... detection of midline shifts in the brain, ... and easy to use, the Sonomed-315 offers ... A-scanning mode allows to identify the anatomic ...
Medicine Products: